Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response.

Usman, M; Syed, N N; Kakepoto, G N; Adil, S N; Khurshid, M

Usman, M; Syed, N N; Kakepoto, G N; Adil, S N; Khurshid, M.

Article in En | IMSEAR | ID: sea-93469

Subject(s)

Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents/pharmacology; Child; Cytogenetic Analysis; Cytogenetics; Female; Fusion Proteins, bcr-abl/drug effects; Gene Targeting; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy; Male; Medical Oncology/trends; Middle Aged; Neoplasm Staging; Piperazines/pharmacology; Prognosis; Prospective Studies; Protein Kinase Inhibitors/pharmacology; Protein-Tyrosine Kinases/antagonists & inhibitors; Pyrimidines/pharmacology; Time Factors; Translocation, Genetic; Treatment Outcome

Fulltext

Add to My VHL

XML

Search on Google

Full text: 1 Index: IMSEAR Main subject: Piperazines / Prognosis / Pyrimidines / Time Factors / Translocation, Genetic / Protein-Tyrosine Kinases / Aged / Female / Humans / Male Type of study: Observational_studies / Prognostic_studies Language: En Year: 2007 Type: Article

Fulltext

Add to My VHL

XML

Search on Google